OptiNose (OPTN)
(Delayed Data from NSDQ)
$1.15 USD
-0.12 (-9.45%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $1.16 +0.01 (0.87%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
OPTN 1.15 -0.12(-9.45%)
Will OPTN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for OPTN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OPTN
OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates
Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates
OPTN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Gain Therapeutics, Inc. (GANX) Report Negative Q1 Earnings? What You Should Know
Will OptiNose (OPTN) Report Negative Q1 Earnings? What You Should Know
OptiNose (OPTN) Reports Q4 Loss, Lags Revenue Estimates
Other News for OPTN
Lake Street Sticks to Its Buy Rating for Optinose (OPTN)
Expanded Access to XHANCE with Addition to National Commercial Formularies
Optinose announces XHANCE added to Express Scripts' national formularies
Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
OptiNose, Inc. (OPTN) Q1 2024 Earnings Call Transcript